下一代测序与多种肺癌诊断中的临床病理评估:系统性审查和元分析
Ziyang Wang1,2,3, Xiaoqiu Yuan1,2,3, Yuntao Nie4
1Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.
Thoracic cancer
|March 21, 2025
概括
分子方法准确地区分了多种原发性肺癌与转移,改善了预后. 生物信息学辅助诊断比传统病理学提供了更高的准确性和生存优势,特别是在高风险患者中.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 诊断病理学的诊断病理学
背景情况:
- 区分多重原发性肺癌 (MPLC) 和肺内转移 (IPM) 对于有效治疗肺癌至关重要.
- 目前的临床病理评估缺乏多重肺癌 (MLC) 的诊断精度和预后价值.
- 分子方法是有前途的,但需要标准化和验证,用于诊断和预后应用.
研究的目的:
- 系统地比较分子方法的诊断和预后性能与诊断MLC的临床病理评估.
- 评估下一代测序 (NGS) 参数对诊断准确性的影响.
- 评估分子评估在MPLC和IPM的分层预后中的有用性.
主要方法:
- 对41项涉及1266名患者的研究进行了系统审查.
- 两种分子方法的比较:Mole1 (手动突变计数) 和Mole2 (生物信息学辅助的克隆概率).
- 用分子诊断作为参考对临床病理学评估的评估.
主要成果:
- 与临床病理学评估相比,分子方法 (Mole1和Mole2) 显示出更高的诊断准确度和预后歧视.
- Mole1通过分层预后显著改善了无疾病生存率 (DFS) 和整体生存率 (OS).
- Mole2表现出高特异性和稳定性 (AUC 0.962-0.979),最小的基因组 (30-50) 可能足以进行预后差异化.
- 临床病理学评估显示出高误诊率 (35.5%和33.6%) 并未有效区分预后.
结论:
- 分子诊断,特别是生物信息学辅助方法,显著提高了区分MPLC和IPM的准确性.
- 建议将分子诊断纳入多学科评估,以提高成本效益和诊断准确性,特别是在高风险病例中.
- 分子评估提供了验证的预后价值,导致更好的患者结果和量身定制的治疗策略.
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...


